Report error Found 75 Enz. Inhib. hit(s) with all data for entry = 12572
TargetBaculoviral IAP repeat-containing protein 2 [254-364](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 0.700nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [254-364](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 0.800nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [254-364](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 0.800nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [254-364](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 1nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [254-364](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 1nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [254-364](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 1nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [254-364](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 1nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [254-364](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 1.10nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [254-364](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 1.20nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [254-364](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 1.20nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [254-364](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 1.20nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [254-364](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 1.30nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [254-364](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 1.30nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [254-364](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 1.30nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [254-364](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 1.30nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [254-364](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 1.40nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [254-364](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 1.40nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3 [236-342](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 1.5nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3 [236-342](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 1.5nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [254-364](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 1.60nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [254-364](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 1.60nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3 [236-342](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 1.60nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3 [236-342](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 1.70nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3 [236-342](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 1.80nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3 [236-342](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 1.90nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [254-364](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 1.90nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [254-364](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 1.90nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [254-364](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 1.90nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3 [236-342](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 2.10nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3 [236-342](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 2.20nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [254-364](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 2.20nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3 [236-342](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 2.20nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [254-364](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 2.30nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3 [236-342](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 2.30nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3 [236-342](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 2.40nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3 [236-342](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 2.60nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3 [236-342](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 2.60nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3 [236-342](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 2.70nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [254-364](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 3nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3 [236-342](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 3.20nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3 [236-342](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 3.80nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3 [236-342](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 4nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3 [236-342](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 5.20nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3 [236-342](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 5.70nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3 [236-342](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 5.80nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3 [236-342](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 6.70nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3 [236-342](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 6.90nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase XIAP [238-358](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 7.10nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3 [236-342](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 7.90nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase XIAP [238-358](Human)
Nanjing China-Australia Institute of Translational Medicine
US Patent
Nanjing China-Australia Institute of Translational Medicine
US Patent
Affinity DataKi: 8.20nMAssay Description:The binding affinity of the compounds provided by the present invention to IAP proteins was determined using a fluorescence polarization method (Niko...More data for this Ligand-Target Pair
